Results 211 to 220 of about 9,103,151 (355)

Revisiting Afghanistan's Drug Policy: A Policy Analysis of Eradication, Harm Reduction, and Economic Dependencies. [PDF]

Health Sci Rep
Azizi MQ, Wardak MF, Afzali E, Rahimi A, Ogaya JB, Ejaz E, Hasin BA, Masudi M, Lucero-Prisno DE.   +8 more
europepmc   +1 more source

Potent and Selective IGF‐IIR‐Recruiting Bifunctional Molecules for Targeted Lysosomal Degradation of Extracellular and Membrane Proteins

Advanced Science, EarlyView.
Lysosome‐targeting chimeras (LYTACs) enable degradation of extracellular and membrane proteins via lysosomal trafficking. We report a novel IGF‐II mutant (Del1–7, Y27L) that selectively engages IGF‐IIR while avoiding IGF‐IR and IR‐A. mutIGF‐II–based LYTACs enhance target internalization and degradation and support a genetically encodable, all‐protein ...
Yuan Zhao, Yaxian Liao, Pengyun Li, Regina Stasser de Gonzalez, Xuankun Chen, Nicholas S. Nieto, Florence M. Brunel, Nick Cox, Joseph Stock, Matthew McHenry, Guangsen Fu, Penghsuan Huang, Wenxin Wu, Deqin Cai, Lingjun Li, Alexander N. Zaykov, Weiping Tang   +16 more
wiley   +1 more source

Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation

Advanced Science, EarlyView.
This target trial emulation in solid organ transplant candidates with obesity and type 2 diabetes evaluates whether pre‐transplant dual therapy with GLP‐1 receptor agonists plus SGLT2 inhibitors is associated with post‐transplant mortality and kidney graft outcomes compared with monotherapy or usual care, using multinational electronic health records ...
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Yen‐Liang Liu, Gideon Meyerowitz‐Katz, Tsung‐Hsun Tsai, Pen‐Hua Su   +7 more
wiley   +1 more source

Germany's cannabis act: a catalyst for European drug policy reform? [PDF]

Lancet Reg Health Eur
Manthey J, Rehm J, Verthein U.
europepmc   +1 more source

The Impact of China's Zero Markup Drug Policy on Hospitalization Expenses for Inpatients in Tertiary Public Hospitals: Evidence Based on Quantile Difference-in-Difference Models. [PDF]

Healthcare (Basel), 2021
Ni Z, Jia J, Cui L, Zhou S, Wang X.
europepmc   +1 more source

Harm reduction drug policy [PDF]

, 2002
-
core  

Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment

Advanced Science, EarlyView.
This review focuses on biomimetic nanomedicines for tumor microenvironment (TME) remodeling, covering their diverse biomimetic types, design principles, and mechanisms of immune cell reprogramming and reversal of immunosuppressive microenvironments, with particular emphasis on their application in synergistic immunotherapy.
Wanrong Wang, Siqi Mu, Juan Zhang, Guisong Shan, Xueqian Li, Ran Wang, Tao Guo, Xiaoyan He   +7 more
wiley   +1 more source

The universal zero markup drug policy and gastric cancer hospitalization expenses: an analysis of trends and influencing factors in Shanghai from 2014 to 2021. [PDF]

BMC Health Serv Res
Gu Y, Hao J, He D, Sun H, Cui X, Tian W, Zhang Y, Jin C, Wang H.   +8 more
europepmc   +1 more source

An assessment of nursing mothers' and young people's access to proprietary and patent medicine vendors' services in rural communities of south-eastern Nigeria: implication for review of national drug policy. [PDF]

J Pharm Policy Pract, 2021
Uneke CJ, Obeka I, Uneke BI, Umeokonkwo A, Nweze CA, Otubo KI, Uguru OE.   +6 more
europepmc   +1 more source

Premium policy? Getting better value from the PBS [PDF]

Overview: Poor implementation of a policy to get better value for PBS spending is costing government $320 million a year and raising questions about pharmaceutical industry involvement in drug pricing. The therapeutic group premium policy, introduced in
Peter Breadon, Stephen Duckett
core